Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food and Quinidine Effect on Balcinrenone/Dapagliflozin PK
NCT06979388Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of balcinrenone in chronic kidney disease (CKD) and heart failure (HF) (6 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time zero to infinity, Area under concentration-curve from time 0 to the last quantifiable concentration and 7 more. Started May 2025; status: completed.
02
Drugs
balcinrenone
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on NCT06979388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06979388.